Explore the words cloud of the EXPERT project. It provides you a very rough idea of what is the project "EXPERT" about.
The following table provides information about the project.
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
|Coordinator Country||Netherlands [NL]|
|Total cost||15˙010˙087 €|
|EC max contribution||14˙931˙337 € (99%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2019-09-01 to 2024-08-31|
Take a look of project's partnership.
|1||UNIVERSITAIR MEDISCH CENTRUM UTRECHT||NL (UTRECHT)||coordinator||2˙363˙251.00|
|2||ETHERNA IMMUNOTHERAPIES||BE (NIEL)||participant||5˙229˙000.00|
|3||SINTEF AS||NO (TRONDHEIM)||participant||1˙153˙906.00|
|4||FUNDACION CIDETEC||ES (SAN SEBASTIAN)||participant||1˙089˙750.00|
|5||TEL AVIV UNIVERSITY||IL (TEL AVIV)||participant||1˙037˙000.00|
|6||ASTRAZENECA AB||SE (SODERTAELJE)||participant||927˙500.00|
|7||THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN||IE (DUBLIN)||participant||755˙805.00|
|8||KAROLINSKA INSTITUTET||SE (STOCKHOLM)||participant||690˙000.00|
|9||SEMMELWEIS EGYETEM||HU (BUDAPEST)||participant||687˙375.00|
|10||EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH||DE (ST INGBERT)||participant||658˙125.00|
The overall objective of EXPERT is to create an off-the-shelf mRNA-delivering nanomedicine platform that is manufactured via a quality-by-design (QbD) approach with precise nanoparticle characterization and specifications that meet the requirements for GMP scaling up and clinical translation. As proof-of-concept we will perform a first-in-man clinical study for an intratumorally administered immunostimulatory mRNA-nanomedicine in cancer patients. The work focuses on the three critical elements of the call “Innovation platforms for advanced therapies of the future” 1. EXPERT investigates mRNAs as therapeutics, which are classified as advanced therapies. 2. By showing proof-of-concept in a clinical trial we aim to meet the technical, industrial and regulatory challenges to develop a mRNA-nanomedicine formulation from bench to bedside. This opens up new treatment possibilities for a large group of cancer patients and paves the way for subsequent formulations strengthening the European advanced therapy R&D. 3. mRNA nanomedicines are a true platform technology. mRNAs are composed of four similar building blocks, resulting in a molecule with predictable qualities. This allows for a platform approach to production, purification, formulation and storage which streamlines the drug development process offering important technological progress in this field. We will encapsulate mRNA into nanocarriers. Thereby, the mRNA is protected and the physicochemical characteristics of the mRNA are overruled by the characteristics of the nanoparticle to enable target cell uptake. We have experience in state-of-the art materials to make mRNA nanomedicines. To address their complexity we will optimize nanoparticle design and manufacture via QbD. We will use microfluidic manufacture as a scalable and reproducible production technology. To characterize and manufacture the mRNA nanomedicines under GMP conditions we will use the EU-ecosystem of designated facilities within EUNCL and NANOP
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EXPERT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EXPERT" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
ENDOSCAPE, a clinically applicable non-viral gene delivery technologyRead More
Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in OsteoarthritisRead More